tezosentan
Jump to navigation
Jump to search
Contraindications
- no clinical benefit for acute heart failure
Dosage
Adverse effects
Mechanism of action
- endothelin receptor antagonist
- inhibits endothelin receptor 1 & endothelin receptor 2
- signficant hemodynamic improvements with tezosentan did not translate to improved clinical outcomes[2]
More general terms
References
- ↑ McMurray JJ et al, for the VERITAS Investigators Effects of tesosentain on symptoms and clinical outcomes in patients with acute heart failure: The VERITAS randomized controlled trials. JAMA 2007, 298:2009 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17986694
- ↑ 2.0 2.1 McMurray JJV et al, Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: The VERTAS randomized controlled trials. JAMA 2007, 2009 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17986694